BeiGene Ltd. ADR (BGNE) News
Filter BGNE News Items
BGNE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BGNE News Highlights
- BGNE's 30 day story count now stands at 5.
- Over the past 13 days, the trend for BGNE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about BGNE are MAX, DRUG and LE.
Latest BGNE News From Around the Web
Below are the latest news stories about BEIGENE LTD that investors may wish to consider to help them evaluate BGNE as an investment opportunity.
The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income CountriesSEATTLE & BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., May 17, 2023--The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global biotechnology company, and the BeiGene Foundation, a nonprofit charitable foundation, today announced a collaboration to provide access to BRUKINSA (zanubrutinib) for the treatment of adult patients with chronic lymphocytic le |
12 Best Fast Growth Stocks to Buy NowIn this article, we will take a look at the 12 best fast growth stocks to buy now. To see more such companies, go directly to 5 Best Fast Growth Stocks to Buy Now. Growth stocks were hammered in 2022 as inflation started to spike and the Federal Reserve began to increase interest rates. While […] |
BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in ChinaBASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., May 06, 2023--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the China National Medical Products Administration (NMPA) approved four applications for BRUKINSA (zanubrutinib), the company’s Bruton’s tyrosine kinase inhibitor (BTKi), including two Supplemental New Drug Applications for treatment-naïve adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and Waldenström' |
BeiGene First Quarter 2023 Earnings: EPS Beats ExpectationsBeiGene ( NASDAQ:BGNE ) First Quarter 2023 Results Key Financial Results Revenue: US$447.8m (up 46% from 1Q 2022). Net... |
BeiGene Reports First Quarter 2023 Financial Results and Corporate DevelopmentsBASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., May 04, 2023--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today reported financial results for the first quarter 2023, recent business highlights, and upcoming milestones. |
BeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual MeetingBASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., April 26, 2023--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, will present data from its broad solid tumor and hematology portfolio at the upcoming American Society of Cancer Oncology (ASCO) Annual Meeting in Chicago, June 2-6, 2023. |
3 Top Biotech Stocks Defying the Bear MarketThe bear market for biotech stocks has recently shown signs of slackening, but there are biotech stocks whose shares are already up by 50% or more to start this year. TG Therapeutics (NASDAQ: TGTX), Viking Therapeutics (NASDAQ: VKTX) and BeiGene (NASDAQ: BGNE) have attracted investors' interest because they all have new therapies with wide applications that have shown great promise. TG Therapeutics' launch of Briumvi, a therapy for relapsing multiple sclerosis, has been a quick success, even with competition from two other anti-CD20 monoclonal antibodies already on the market. |
BeiGene Announces Goals Focused on Sustainable Growth and Workforce Diversity in New ESG ReportBASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., April 25, 2023--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, announced several new Environmental, Social, and Governance (ESG) goals today, including targets related to carbon emissions and workforce diversity. These goals are outlined in the Company’s newly released "Change Is the Cure: 2022 Environmental, Social and Governance Report." The report highlights BeiGene’s ESG strategy, the progress the Company has |
BeiGene's Tislelizumab/Chemo Combo Hits Primary Goal In Gastric Cancer StudyBeiGene Ltd's (NASDAQ: BGNE) global RATIONALE 305 Phase 3 trial met its primary endpoint of overall survival, with tislelizumab in combination with chemotherapy in patients with advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, regardless of PD-L1 status. No new safety signals were identified for tislelizumab. BeiGene previously announced superior OS for the combination compared with chemotherapy in the PD-L1 high group at a planned interim analysis |
BeiGene Announces Positive Phase 3 Tislelizumab Trial in Advanced Gastric or Gastroesophageal Junction AdenocarcinomaBASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., April 20, 2023--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the global RATIONALE 305 trial met its primary endpoint of overall survival, with tislelizumab in combination with chemotherapy demonstrating superior overall survival (OS) compared with chemotherapy in patients with advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, regardless of PD-L1 sta |